Exagen Inc.
NASDAQ:XGNMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $99.50M
- Beta
- 2.02
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.85
Volume 0.47M
Average 0.39M
XGN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Exagen Inc.NASDAQ: XGN
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $599K rose 36.1% year over year, ahead of the +33.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.2% from the prior quarter. Over 3 fiscal years it compounded at +10.8% a year.
Context
- Depreciation & amortization amounted to 3.2% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +36.1% holds above the trailing-twelve-month pace of +33.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 2.12M USD
- Year-over-year change
- +22.9%
- 4-year CAGR
- +22.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.12M | +22.9% |
| FY2024 | 2024-12-31 | 1.72M | -20.5% |
| FY2023 | 2023-12-31 | 2.17M | +39.2% |
| FY2022 | 2022-12-31 | 1.56M | +64.2% |
| FY2021 | 2021-12-31 | 948K | — |
Depreciation & Amortization vs competitors
How XGN compares with its peers on the latest reported figures
- XGN's LTM Mar 2026 depreciation & amortization of $2.28M is the 7th largest of the 11 companies compared; the peer median is $7.5M.
- Its year-over-year change of +33.5% is the 3rd highest of 10, against a peer median of +9.7%.
- Depreciation & amortization amounts to 3.3% of revenue for XGN, versus a peer median of 6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $65.46M | -8.0% | -0.8% | 8.5% | |
| LTM Mar 2026 | $28.02M | +456.0% | +129.2% | 26.1% | |
| LTM Mar 2026 | $9.76M | — | -23.7% | 7.2% | |
| FY2025 | $9.21M | +14.5% | +23.3% | 8.5% | |
| LTM Mar 2026 | $8.66M | +9.7% | — | 4.0% | |
| LTM Mar 2026 | $6.34M | -2.8% | +26.1% | 15.2% | |
| LTM Mar 2026 | $2.28M | +33.5% | +10.8% | 3.3% | |
| LTM Mar 2026 | $1.58M | +31.8% | +53.6% | 5.1% | |
| LTM Mar 2026 | $690K | +3.1% | -11.8% | 0.9% | |
| LTM Mar 2026 | $528K | -25.9% | -17.1% | 6.3% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $239K | +39.8% | +18.2% | 2.3% |
| Peer median (excluding XGN) | $7.5M | +9.7% | +18.2% | 6.8% | |
Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.85M) | (47.39M) | (23.69M) | (15.12M) | (19.95M) |
| Depreciation & Amortization | 948K | 1.56M | 2.17M | 1.72M | 2.12M |
| Deferred Income Tax | 148K | (306K) | 0 | 0 | 0 |
| Stock-Based Compensation | 4.73M | 4.7M | 3.62M | 1.76M | 2.16M |
| Change in Working Capital | (61K) | 1.67M | 325K | (3.08M) | (1.98M) |
| Accounts Receivables | (744K) | 3.58M | (474K) | (1.28M) | (3.02M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (655K) | 901K | 67K | 308K | 42K |
| Other Working Capital | 1.34M | (2.81M) | 732K | (2.1M) | 997K |
| Other Non-Cash Items | 819K | 7.62M | 3.12M | 1.43M | 4.03M |
| Operating Cash Flow | (20.27M) | (32.14M) | (14.46M) | (13.28M) | (13.63M) |
| Capital Expenditures | (2.37M) | (4.32M) | (828K) | (515K) | (641K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 15K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (50K) | 0 | 24K | 0 | 0 |
| Investing Cash Flow | (2.42M) | (4.32M) | (804K) | (515K) | (626K) |
| Debt Repayment | (525K) | (696K) | (10.94M) | (861K) | 2.01M |
| Common Stock Issued | 69.14M | 446K | 306K | 198K | 22.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.94M) | (239K) | 0 | 0 | 0 |
| Financing Cash Flow | 64.68M | (489K) | (10.63M) | (663K) | 24.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 41.99M | (36.95M) | (25.9M) | (14.46M) | 10.18M |
| Free Cash Flow | (22.64M) | (36.46M) | (15.29M) | (13.79M) | (14.27M) |
Exagen Inc.
NASDAQ:XGN
Intrinsic Alpha fair value
Locked
Current Price
$3.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.